Comparable stake leader
Samsara BioCapital, L.P.
SEC ownership of PMV Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001699382.
Disclosed value leader
INTERWEST PARTNERS X LP
Comparable rows
6/50
Latest evidence
02 Sep 2026
- Public ticker
- PMVP on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Samsara BioCapital, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Samsara BioCapital, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001699382
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PMV Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Samsara BioCapital, L.P.
Disclosed value leader
INTERWEST PARTNERS X LP
Comparable rows
6/50
Latest evidence
02 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
44 rows are not safely comparable across share classes.
13D/G row: Samsara BioCapital, L.P.
Showing 1-8 of 50 holder rows.
Quick read
Samsara BioCapital, L.P. leads the comparable SEC ownership view at 9.9%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Samsara BioCapital, L.P.'s linked filing trail.
Comparable ownership
Top 5
Samsara BioCapital, L.P.
9.9%
BML Investment Partners, L.P.
9.9%
TANG CAPITAL MANAGEMENT LLC
8.9%
Sio Capital Management, LLC
4.9%
Euclidean Capital LLC
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P. |
13D/G
Srinivas Akkaraju
|
9.9%
Reported 13D/G
· 02 Sep 2026
|
$9,547,608
7,577,467 shares
|
$0 | 02 Sep 2026 |
| BML Investment Partners, L.P. |
13D/G
|
9.9%
Reported 13D/G
· 31 Dec 2025
|
$6,615,000
5,292,000 shares
|
+$2,527,616 | 31 Dec 2025 |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
8.9%
Reported 13D/G
· 16 Sep 2025
|
$6,702,907
4,720,357 shares
|
$0 | 16 Sep 2025 |
| Sio Capital Management, LLC |
13F
13D/G
Company
|
4.9%
Reported 13D/G
· 30 Jun 2026
|
$3,529,744
2,634,137 shares
|
— | 30 Jun 2026 |
| Euclidean Capital LLC |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
4.9%
Reported 13D/G
· 31 Mar 2026
|
$3,521,042
2,627,643 shares
|
— | 30 Jun 2026 |
| ArrowMark Colorado Holdings LLC |
13F
13D/G
Company
|
3.7%
Reported 13D/G
· 30 Jun 2026
|
$2,625,836
1,959,579 shares
|
— | 30 Jun 2026 |
| INTERWEST PARTNERS X LP |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$10,040,531
4,502,480 shares
|
— | 13 Jul 2021 |
| ORBIMED ADVISORS LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$7,562,442
4,975,291 shares
|
— | 23 Oct 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 02 Nov 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to PMV Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
INTERWEST PARTNERS X LP
Net 12M change
$0
Latest report
01 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| INTERWEST PARTNERS X LP | 10%+ Owner | $10,040,531 | Mixed | 13 Jul 2021 | ||
| ORBIMED ADVISORS LLC | 10%+ Owner | $7,562,442 | Filing P/S | 23 Oct 2025 | ||
| Thilo Schroeder | Director | $2,455,861 | Mixed | 06 Oct 2021 | ||
| David Henry Mack | President and CEO, Director | $697,788 | Mixed | 05 Mar 2026 | ||
| Euclidean Capital LLC | 10%+ Owner | $283,431 | Mixed | 11 Jun 2021 | ||
| Robert Ticktin | General Counsel & COO | $105,090 | Filing P/S | 05 Mar 2026 | ||
| Leila Alland | Chief Medical Officer | $102,377 | Mixed | 15 Sep 2023 | ||
| Deepika Jalota | Chief Development Officer | $95,761 | Filing P/S | 05 Mar 2026 | ||
| Michael Carulli | Chief Financial Officer | $92,310 | Mixed | 05 Mar 2026 | ||
| Matthew Joseph Eckler | Director | Mixed | 01 Oct 2026 | |||
| Laurie Stelzer | Director | Mixed | 04 Jun 2026 | |||
| Arnold J. Levine | Director | Mixed | 04 Jun 2026 | |||
| Carol Giltner Gallagher | Director | Mixed | 04 Jun 2026 | |||
| Richard A. Heyman | Director | Mixed | 05 Jun 2025 | |||
| Winston Kung | Coo, Cfo | Mixed | 12 May 2023 | |||
| Peter A. Thompson | Director, 10%+ Owner | Mixed | 02 Jun 2021 | |||
| Kirsten Flowers | Director | Mixed | 04 Jun 2026 | |||
| Charles M. Baum | Director | Mixed | 04 Jun 2026 |
Recent insider transactions for PMV Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Matthew Joseph Eckler | PMVP | Stock Option (right to buy) | Award | 84,000 | 84,000 | 01 Oct 2026 | Direct | |||
| Laurie Stelzer | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Arnold J. Levine | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Gift | 42,000 | 42,000 | 04 Jun 2026 | See footnote | |||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Gift | -100% | -42,000 | 0 | 04 Jun 2026 | Direct | ||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Kirsten Flowers | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Charles M. Baum | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Michael Carulli | PMVP | Employee Stock Option (right to buy) | Award | 240,000 | 240,000 | 05 Mar 2026 | Direct | |||
| Robert Ticktin | PMVP | Employee Stock Option (right to buy) | Award | 319,270 | 319,270 | 05 Mar 2026 | Direct | |||
| Deepika Jalota | PMVP | Employee Stock Option (right to buy) | Award | 303,310 | 303,310 | 05 Mar 2026 | Direct | |||
| David Henry Mack | PMVP | Employee Stock Option (right to buy) | Award | 744,960 | 744,960 | 05 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.